Credit Suisse analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $170 to $175.
Credit Suisse raises Johnson & Johnson (NYSE:JNJ) price target from $170 to $175 Read Post »
JPMorgan Adjusts Price Target on Johnson & Johnson (NYSE:JNJ) to $180 From $175, Maintains Neutral Rating。
JPMorgan Adjusts Price Target on Johnson & Johnson (NYSE:JNJ) to $180 From $175 Read Post »
Morgan Stanley analyst Terence Flynn reiterates Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and maintains $187 price target.
Morgan Stanley maintains Johnson & Johnson (NYSE:JNJ) $187 price target Read Post »
Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $181 to $184.
Raymond James raises Johnson & Johnson (NYSE:JNJ) price target from $181 to $184 Read Post »
Bank of America Securities analyst Ying Huang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $350 to $400.
Truist Financial analyst Gregg Gilbert maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $430 to $525.
Truist Financial raises Eli Lilly (NYSE:LLY) price target from $430 to $525 Read Post »
Morgan Stanley analyst David Phung maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $551 to $560.
Morgan Stanley raises Eli Lilly (NYSE:LLY) price target from $551 to $560 Read Post »
Jefferies analyst Akash Tewari maintains Eli Lilly (NYSE:LLY) with a Hold and raises the price target from $408 to $430.
Jefferies raises Eli Lilly (NYSE:LLY) price target from $408 to $430 Read Post »
Intuitive Surgical (NASDAQ:ISRG) reported Q2 non-GAAP earnings of $1.42 per diluted share, up from $1.14 a year earlier. Analysts polled by Capital IQ expected $1.33. Revenue for the quarter ended June 30 was $1.76 billion, up from $1.52 billion a year earlier. Analysts surveyed by Capital IQ expected $1.74 billion.
Intuitive Surgical (NASDAQ:ISRG) Q2 Non-GAAP Earnings, Revenue Advance Read Post »
Abbott Laboratories (NYSE:ABT) reported Q2 adjusted earnings Thursday of $1.08 per diluted share, down from $1.43 a year earlier. Analysts polled by Capital IQ expected adjusted EPS of $1.05. Net sales for the quarter ended June 30 were $9.98 billion, down from $11.26 billion a year earlier. Analysts surveyed by Capital IQ expected $9.72 billion. For the full-year 2023, the company reaffirmed its adjusted EPS guidance of $4.30 to $4.50. Analysts surveyed by Capital IQ expect $4.40.
Johnson & Johnson (NYSE:JNJ) reported fiscal Q2 adjusted earnings of $2.80 per diluted share, up from $2.59 a year earlier. Analysts polled by Capital IQ expected $2.62. Sales for the quarter ended July 2 were $25.53 billion, up from $24.02 billion a year earlier. Analysts surveyed by Capital IQ expected $24.67 billion. Johnson & Johnson (NYSE:JNJ) said it now expects fiscal 2023 adjusted earnings of $10.70 to $10.80 per diluted share, compared with its prior guidance of $10.60 to $10.70 per diluted share. Analysts polled by Capital IQ are looking for $10.65. Sales for the fiscal year are now projected to be $98.8 billion to $99.8 billion, compared with $97.9 billion to $98.9 billion previously, the company said. Analysts surveyed by Capital IQ are expecting $98.91 billion.
Deutsche Bank analyst George Hill maintains UnitedHealth Group (NYSE:UNH) with a Buy and lowers the price target from $564 to $555.
Deutsche Bank lowers UnitedHealth Group (NYSE:UNH) price target from $564 to $555 Read Post »